News

We’re excited to share ALLG News Edition 11! This issue highlights our ongoing commitment to groundbreaking blood cancer research, innovative clinical trials, and community support.

In recognition of World Cancer Day 2025, Dr Chyn Chua (Chair of ALLG’s Acute Leukaemia/MDS Scientific Working Party) delivered an insightful presentation on the ALLG AMLM26 INTERCEPT trial. This game-changing trial uses cutting-edge genomic and clonal screening to personalise cancer treatment, helping to prevent relapse with targeted therapies.

Our newly released compendium, ‘Five Decades of Impactful Published Research’, showcases ALLG’s contributions to leukaemia, lymphoma, and myeloma treatment. For over 50 years, we’ve generated high-quality evidence that has shaped global standards in blood cancer care.

Every day, our researchers strive to deliver better treatments, improve lives, and work toward a cure.

ALLG News Edition 11 Insights

Find out how our research has earned ALLG a reputation as Global Leaders with Global Impact by reading about our latest trial publication in Blood Advances. The Acute Promyelocytic Leukaemia AMPL5 study, led by Professor Harry Iland, investigated an oral medication alternative to intravenous treatment, improving outcomes and quality of life for patients.

Read about how we are committed to supporting the next generation of blood cancer researchers through our HSANZ Clinical Trials Fellowship Program and our Early Career Clinician Researcher Program. These key programs equip early-career clinicians with the skills and opportunities to drive new treatment discoveries. Stay tuned for the announcement of our latest intake of Early Career Clinician Researchers!

Discover how you can support our vital blood cancer research through social media fundraising, PayPal donations and Twitch streaming fundraisers. Your contributions help fund vital research and clinical trials that bring hope and new treatment options to those impacted by blood cancer.

Read more by downloading our ALLG News, Edition 11.

 

ALLG’s Impact – Blood Cancer Research

ALLG is Australasia’s only not-for-profit, collaborative blood cancer clinical trial group. For over 50 years, we have played a pivotal role in transforming blood cancer treatment worldwide. In the past year alone, our researchers have supported 1,061 patients and managed a portfolio of over 75 clinical trials.

With a dedicated membership of 1,452 doctors and healthcare professionals, ALLG is committed to advancing clinical trial research that leads to better treatments and better lives for patients.

Research is the key to progress in blood cancer treatment, and clinical trials serve as the vital bridge between laboratory breakthroughs and real-world patient care. Visit ALLG to learn more about our mission and discover how you can support our research.